Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
NEW YORK (Reuters Health) – Postmenopausal breast cancer patients taking aromatase inhibitors have increased risks for carpal tunnel syndrome and new or worsening arthralgia, two studies published online…
NEW YORK (Reuters Health) – The combination of pentoxifylline and vitamin E prevented radiation-induced lymphedema among breast cancer patients in a phase II trial in Sweden. The finding…
NEW YORK (Reuters Health) – New research indicates that the outcomes of localized prostate cancer following conservative management have improved in the last few decades. According to the…
NEW YORK (Reuters Health) – Particle beam radiation has been available since 1954, but a systematic literature review has failed to turn up statistically or clinically significant differences…
NEW YORK (Reuters Health) – Findings from a systematic review indicate that while tamoxifen, raloxifene, and tibolone all reduce the risk of primary breast cancer, the drugs differ…
NEW YORK (Reuters Health) – A dexamethasone-based protocol can cut the risk of relapse and improve survival in high-risk children with acute lymphoblastic leukemia (ALL), with fewer side…
NEW YORK (Reuters Health) – As a treatment for renal tumors, robot-assisted partial nephrectomy (RAPN) offers comparable oncologic control as traditional laparoscopic nephrectomy, but with less blood loss,…
NEW YORK (Reuters Health) – Doubling the standard dose of fluvestrant improves the efficacy of the drug against breast cancer without affecting tolerability, new research suggests. Moroever, at…
NEW YORK (Reuters Health) – It’s possible that more than 1 million men in the US have been needlessly treated for prostate cancer since the late 1980s, when…
NEW YORK (Reuters Health) – Nadroparin, a low-molecular-weight heparin, reduces the incidence of thromboembolic events in ambulatory patients receiving chemotherapy for metastatic or locally advanced solid cancers, an…
